Estados Unidos - inglés - NLM (National Library of Medicine)

bryant ranch prepack - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate/salmeterol multidose dry powder inhaler (fs mdpi) is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. fluticasone propionate/salmeterol mdpi should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta2 -adrenergic agonist (laba). limitations of use : fluticasone propionate/salmeterol mdpi is not indicated for the relief of acute bronchospasm. fluticasone propionate/salmeterol mdpi is contraindicated in: - the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required [see warnings and precautions  (5.2)] . - patients with known severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to fluticasone propionate or any of the excipients [see warnings and precautions (5.10) and description (11)]

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/50 microgram(s)/dose - salmeterol and fluticasone

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

generics (uk) limited - salmeterol xinafoate ; fluticasone propionate - pressurised inhalation suspension - 25mcg/125 microgram - salmeterol and fluticasone

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

generics (uk) limited - salmeterol xinafoate ; fluticasone propionate - pressurised inhalation suspension - 25mcg/250 microgram - salmeterol and fluticasone

Australia - inglés - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. seroflo ciphaler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include,? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. seroflo multihaler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Malta - inglés - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - salmeterol, fluticasone propionate - inhalation powder - salmeterol 50 µg fluticasone propionate 500 µg - drugs for obstructive airway diseases

Malta - inglés - Medicines Authority

generics uk limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg; fluticasone propionate 125 µg - drugs for obstructive airway diseases

Malta - inglés - Medicines Authority

generics uk limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg; fluticasone propionate 250 µg - drugs for obstructive airway diseases

Estados Unidos - inglés - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u), salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate and salmeterol inhalation powder should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate and salmeterol inhalation powder is not indicated for the relief of acute bronchospasm. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. flut